MX2022006151A - Derivados de 1,2,4-oxadiazol como agonistas del receptor hepatico x. - Google Patents
Derivados de 1,2,4-oxadiazol como agonistas del receptor hepatico x.Info
- Publication number
- MX2022006151A MX2022006151A MX2022006151A MX2022006151A MX2022006151A MX 2022006151 A MX2022006151 A MX 2022006151A MX 2022006151 A MX2022006151 A MX 2022006151A MX 2022006151 A MX2022006151 A MX 2022006151A MX 2022006151 A MX2022006151 A MX 2022006151A
- Authority
- MX
- Mexico
- Prior art keywords
- liver
- receptor agonists
- oxadiazole derivatives
- compound
- formula
- Prior art date
Links
- 150000005071 1,2,4-oxadiazoles Chemical class 0.000 title 1
- 239000000766 liver X receptor agonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 206010065062 Meibomian gland dysfunction Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962940061P | 2019-11-25 | 2019-11-25 | |
| US202063106293P | 2020-10-27 | 2020-10-27 | |
| PCT/IB2020/061053 WO2021105857A1 (en) | 2019-11-25 | 2020-11-23 | 1,2,4-oxadiazole derivatives as liver x receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022006151A true MX2022006151A (es) | 2022-08-02 |
Family
ID=73654860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022006151A MX2022006151A (es) | 2019-11-25 | 2020-11-23 | Derivados de 1,2,4-oxadiazol como agonistas del receptor hepatico x. |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11427586B2 (https=) |
| EP (1) | EP4065228A1 (https=) |
| JP (1) | JP2023503320A (https=) |
| KR (1) | KR20220106778A (https=) |
| CN (1) | CN114746149A (https=) |
| AU (1) | AU2020394597B2 (https=) |
| BR (1) | BR112022009942A2 (https=) |
| CA (1) | CA3157657A1 (https=) |
| CL (1) | CL2022001323A1 (https=) |
| CO (1) | CO2022006645A2 (https=) |
| CR (1) | CR20220227A (https=) |
| DO (1) | DOP2022000107A (https=) |
| EC (1) | ECSP22040362A (https=) |
| IL (1) | IL291958A (https=) |
| JO (1) | JOP20220124A1 (https=) |
| MX (1) | MX2022006151A (https=) |
| PE (1) | PE20221785A1 (https=) |
| PH (1) | PH12022551248A1 (https=) |
| PY (1) | PY2077235A (https=) |
| TW (1) | TW202132289A (https=) |
| UY (1) | UY38964A (https=) |
| WO (1) | WO2021105857A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024518128A (ja) * | 2021-05-20 | 2024-04-24 | ノバルティス アーゲー | ３－（（３－（４－（２－（イソブチルスルホニル）フェノキシ）－３－（トリフルオロメチル）フェニル）－１，２，４－オキサジアゾール－５－イル）メチル）－５，５－ジメチル－１－（２－モルホリノエチル）イミダゾリジン－２，４－ジオンの製剤 |
| WO2022249006A1 (en) * | 2021-05-24 | 2022-12-01 | Novartis Ag | Use of 1,2,4-oxadiazole derivatives as liver x receptor agonists |
| KR102882404B1 (ko) | 2022-10-28 | 2025-11-06 | (주)케이메디켐 | 신규 옥사디아졸 유도체, 이의 제조방법 및 이를 포함하는 인지기능 개선용 조성물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201120016A (en) | 2009-12-08 | 2011-06-16 | Abbott Lab | Novel oxadiazole compounds |
| US8729109B2 (en) * | 2011-09-08 | 2014-05-20 | Allergan, Inc. | 3-(4-(5-phenyl-1 ,2,4-oxadiazol-3-yl)phenoxy)propan-2-ol derivatives as sphingosine-1phosphate receptors modulators |
| WO2013131018A1 (en) | 2012-03-02 | 2013-09-06 | Zalicus Pharmaceuticals Ltd. | Biaryl inhibitors of the sodium channel |
| WO2015187840A2 (en) * | 2014-06-03 | 2015-12-10 | Duke University | Methods and formulations for treatment of ocular disorders |
| JP2022514257A (ja) | 2018-12-13 | 2022-02-10 | アイノス，インコーポレイテッド | ドライアイ疾患の治療のための局所点眼製剤におけるｌｘｒアゴニスト |
-
2020
- 2020-11-20 PY PY202002077235A patent/PY2077235A/es unknown
- 2020-11-20 UY UY0001038964A patent/UY38964A/es not_active Application Discontinuation
- 2020-11-23 KR KR1020227020461A patent/KR20220106778A/ko not_active Ceased
- 2020-11-23 CN CN202080081467.7A patent/CN114746149A/zh active Pending
- 2020-11-23 BR BR112022009942A patent/BR112022009942A2/pt not_active Application Discontinuation
- 2020-11-23 JP JP2022529931A patent/JP2023503320A/ja active Pending
- 2020-11-23 EP EP20817082.9A patent/EP4065228A1/en not_active Withdrawn
- 2020-11-23 CR CR20220227A patent/CR20220227A/es unknown
- 2020-11-23 IL IL291958A patent/IL291958A/en unknown
- 2020-11-23 TW TW109140930A patent/TW202132289A/zh unknown
- 2020-11-23 PH PH1/2022/551248A patent/PH12022551248A1/en unknown
- 2020-11-23 AU AU2020394597A patent/AU2020394597B2/en not_active Expired - Fee Related
- 2020-11-23 US US17/101,510 patent/US11427586B2/en active Active
- 2020-11-23 CA CA3157657A patent/CA3157657A1/en active Pending
- 2020-11-23 WO PCT/IB2020/061053 patent/WO2021105857A1/en not_active Ceased
- 2020-11-23 PE PE2022000828A patent/PE20221785A1/es unknown
- 2020-11-23 MX MX2022006151A patent/MX2022006151A/es unknown
-
2022
- 2022-05-19 EC ECSENADI202240362A patent/ECSP22040362A/es unknown
- 2022-05-19 CO CONC2022/0006645A patent/CO2022006645A2/es unknown
- 2022-05-19 CL CL2022001323A patent/CL2022001323A1/es unknown
- 2022-05-20 DO DO2022000107A patent/DOP2022000107A/es unknown
- 2022-05-23 JO JOP/2022/0124A patent/JOP20220124A1/ar unknown
- 2022-06-06 US US17/805,487 patent/US20220340573A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP4065228A1 (en) | 2022-10-05 |
| US11427586B2 (en) | 2022-08-30 |
| JOP20220124A1 (ar) | 2022-05-23 |
| AU2020394597B2 (en) | 2024-03-14 |
| TW202132289A (zh) | 2021-09-01 |
| ECSP22040362A (es) | 2022-06-30 |
| PY2077235A (es) | 2022-10-31 |
| CO2022006645A2 (es) | 2022-05-31 |
| PH12022551248A1 (en) | 2023-09-11 |
| US20220340573A1 (en) | 2022-10-27 |
| UY38964A (es) | 2021-06-30 |
| CN114746149A (zh) | 2022-07-12 |
| IL291958A (en) | 2022-06-01 |
| JP2023503320A (ja) | 2023-01-27 |
| DOP2022000107A (es) | 2022-06-15 |
| AU2020394597A1 (en) | 2022-06-02 |
| CL2022001323A1 (es) | 2023-03-24 |
| CA3157657A1 (en) | 2021-06-03 |
| PE20221785A1 (es) | 2022-11-22 |
| WO2021105857A1 (en) | 2021-06-03 |
| BR112022009942A2 (pt) | 2022-08-09 |
| KR20220106778A (ko) | 2022-07-29 |
| CR20220227A (es) | 2022-06-15 |
| US20220064164A1 (en) | 2022-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2022000107A (es) | Derivados de 1,2,4oxadiazol como agonistas del receptor hepático x | |
| CL2023001738A1 (es) | Inhibidores de prmt5 | |
| MX2023006145A (es) | Inhibidores de prmt5 novedosos. | |
| ECSP21080535A (es) | Compuestos y métodos para el tratamiento de covid-19 | |
| PE20191541A1 (es) | Composiciones y metodos para inhibir la accion de la arginasa | |
| MX2022006736A (es) | Combinacion de un antagonista del receptor lpa1 de azetidina con pirfenidona y/o nintedanib para su uso en el tratamiento de enfermedades fibroticas. | |
| AR069490A1 (es) | Agonistas de los receptores de glucocorticoides | |
| CL2008001669A1 (es) | Compuestos derivados de piperidina/piperazina inhibidora de dgat-1; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento de la obesidad, dislipidemia, fibrosis hepatica y diabetes tipo ii, entre otras. | |
| PY1737795A (es) | Solución de dexmedetomidina lista para el uso, premezclada, esterilizable por calor, envasada en un recipiente de plástico flexible | |
| AR101674A1 (es) | Uso de un compuesto tricíclico que contiene nitrógeno | |
| AR077138A1 (es) | Composiciones farmaceuticas utiles para tratar el vhc | |
| MX2023014492A (es) | Compuestos utiles en la terapia para el vih. | |
| ECSP13012538A (es) | Combinaciones que contienen n-(2-arilamino)arilsulfonamida sustituida | |
| MX2021005240A (es) | Combinacion de inhibidores de peque?as moleculas cd-47 con otros agentes anticancer. | |
| MX389553B (es) | Composicion para incrementar la expresion de pgc-1alfa | |
| CO2018001700A2 (es) | Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos | |
| MX2021006724A (es) | Compuestos de halo-alilamina y uso de los mismos. | |
| MX2022003617A (es) | Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento o mejora del cancer. | |
| AR056369A1 (es) | Compuestos derivados de quinazolina y composicion farmaceutica | |
| AR117844A1 (es) | Derivados de tiazolopiridina como antagonistas del receptor de adenosina | |
| AR127431A1 (es) | Compuestos novedosos | |
| MX2023011377A (es) | Derivados de ciclobutilo 1,3-sustituidos y sus usos. | |
| CO2024001017A2 (es) | Compuestos terapéuticos y procedimientos | |
| DOP2025000235A (es) | Nuevo compuesto, y una composición farmacéutica para la prevención o el tratamiento del cáncer o tumores que comprende el mismo | |
| DOP2022000073A (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 |